NCT07624617NARecruiting
Fast-Her: Fasting Effects on Breast Cancer Treatment
University of Minnesota
Start Date
5/18/2026
Completion Date
7/1/2027
Summary
We hypothesize that promoting a fasting state will strengthen the anti-cancer effects of PI3K inhibitors in metastatic breast cancer (MBC) treatment. The primary objective of this study is to assess acceptability of prolonged fasting in this population.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
* Age ≥18 years
* Histologically confirmed metastatic breast cancer
* Menopausal or medically ovarian suppressed
* Currently receiving capivasertib therapy (2 tablets twice daily, 4 days per week)
* Stable on current capivasertib regimen for at least 2 weeks
* an ECOG performance status of 0-1
* BMI ≥25kg/m2
* Able to provide informed consent
* Willing to comply with study procedures including CGM wear, food tracking by mCC app and dietary modifications
* Access to smartphone or tablet for mobile application use
Exclusion Criteria:
* Type 1 diabetes mellitus
* Uncontrolled type 2 diabetes (HbA1c \>9.0%)
* History of severe hypoglycemia
* Eating disorders or contraindications to fasting
* Pregnancy or breastfeeding
* Significant gastrointestinal disorders affecting food absorption
* Unable to fast for medical reasons
* Concurrent participation in other dietary intervention studies
* A history of significantly abnormal lab results within 4 weeks of consent date, such as hematologic (Hgb \< 10.0, platelets \< 100), hepatic (LFTs \> 2X nl), renal (Cr \> 1.5)
Interventions
BEHAVIORAL
Normal Eating
BEHAVIORAL
Prolonged Fasting
Conditions
Metastatic Breast Cancer
Locations
University of Minnesota
Minneapolis, Minnesota 55455
United States